Characterization of Plasmodium Falciparum Resistance Genes to Common Antimalarial Drugs in Semi-urban Areas of Burkina Faso.
Plasmodium falciparum
Antimalarial
Burkina Faso
Gene
Resistance
Journal
Acta parasitologica
ISSN: 1896-1851
Titre abrégé: Acta Parasitol
Pays: Switzerland
ID NLM: 9301947
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
received:
07
11
2023
accepted:
31
01
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
aheadofprint
Résumé
Malaria still remains the most frequent parasitic disease on the world with, in 2022, 249 million cases and 608,000 deaths worldwide. Malaria control is compromised by the spread of the parasite's resistance to available antimalarials. The objective of our study is to characterize the Plasmodium falciparum resistance genes to common antimalarial drugs in semi-urban areas of Burkina Faso. This is a prospective cross-sectional study whose collection took place from June to October 2021 and from June to October 2022 in five health facilities in Burkina Faso. The molecular analysis based on PCR-RFLP took place from January to June 2023 at Centre National de Recherche et de Formation (CNRFP) to determine resistance genes such as Pfcrt, Pfmdr1, Pfdhps, and Pfdhfr. A total of 150 samples were analyzed giving a prevalence of 46.67, 1.33, 0.67, 20, 82, and 4.67%, for Pfcrt 76 T, Pfmdr1 86Y, Pfdhps 437G, Pfdhfr 51I, Pfdhfr 59R, and Pfdhfr 108N mutations, respectively. There are no mutations observed Pfdhps 540E and Pfdhfr 164L positions. However, mutation on Pfdhfr 59R position was the most common. In addition, triple mutation (Pfdhps 437G + Pfdhfr 59R + Pfdhfr 108N) was found with a low frequency which is 0.67%. Surveillance of Plasmodium falciparum resistance markers to antimalarial drugs, remains one of the priorities in the context of the control or malaria elimination.
Identifiants
pubmed: 38478177
doi: 10.1007/s11686-024-00826-x
pii: 10.1007/s11686-024-00826-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Greenwood BM, Bojang K, And WCJ, Targett GA (2005) Malaria. Lancet 365(9469):1487–1498
doi: 10.1016/S0140-6736(05)66420-3
pubmed: 15850634
OMS (2023) Le rapport sur le paludisme dans le monde. www.who.int/malaria/publications
Ministère de la santé Burkina faso (2023) Rapport de la revue du Programme National de lutte contre le Paludisme
OMS (2001) Les combinaisons thérapeutiques antipaludiques. Rapport d’une consultation technique de l’OMS. Document OMS/CDS/RBM/35
OMS (2003) Évaluation et surveillance de l’efficacité des antipaludiques pour le traitement du paludisme à Plasmodium falciparum non compliqué. Document OMS/RBM/HTM/50
Ministère de la Santé, PNLP Burkina Faso (2006) Directives nationales de la prise en charge du paludisme au Burkina Faso. Version révisée
Ruizendaal E, Tahita MC, Geskus RB, Versteeg I, Scott S, d’Alessandro U et al (2017) Increase in the prevalence of mutations associated with sulfadoxine–pyrimethamine resistance in Plasmodium falciparum isolates collected from early to late pregnancy in Nanoro. Burkina Faso Malar J 16:179. https://doi.org/10.1186/s12936-017-1831-y
doi: 10.1186/s12936-017-1831-y
pubmed: 28454537
Denis MB, Tsuyuoka R, Poravuth Y, NarannTS SS, Lim C et al (2006) Surveillance of the Efficacy of artesunate and Mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 11(9):1360–1366
doi: 10.1111/j.1365-3156.2006.01690.x
pubmed: 16930257
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J et al (2009) Artemisinin resistance in P. falciparum malaria. N Engl J Med 361(5):455–467
doi: 10.1056/NEJMoa0808859
pubmed: 19641202
pmcid: 3495232
Noedl H, Socheat D, Satimai W (2009) Artemisinin-resistant malaria in Asia. N Engl J Med 361(5):540–541
doi: 10.1056/NEJMc0900231
pubmed: 19641219
Ochong EO, Van Den Broek IV, Keus K, Nzila A (2003) Short report: association between chloroquine and amodiaquine resistance and allelic variation in the P. falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg 69:184–187
doi: 10.4269/ajtmh.2003.69.184
pubmed: 13677373
Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N et al (2014) A molecular marker of artemisinin-resistant P. falciparum malaria. Nature 505:50–55
doi: 10.1038/nature12876
pubmed: 24352242
Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C et al (2015) Genetic architecture of artemisinin-resistant P. falciparum. Nat Genet 47:226–234
doi: 10.1038/ng.3189
pubmed: 25599401
pmcid: 4545236
Somé AF, Séré YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B et al (2010) Selection of known P. falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine–pyrimethamine but not dihydroartemisinin–piperaquine in Burkina Faso. Antimicrob Agents Chemother 54(5):1949–1954
doi: 10.1128/AAC.01413-09
pubmed: 20231394
pmcid: 2863637
Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-Ratto C, Mbonye MK et al (2015) In vivo selection of P. falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin–piperaquine in Burkina Faso. Antimicrob Agents Chemother 59:734–737
doi: 10.1128/AAC.03647-14
pubmed: 25403659
Somé AF, Sorgho H, Zongo I, Bazié T, Nikiéma F, Sawadogo A et al (2016) Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso. Parasite 23:60
doi: 10.1051/parasite/2016069
pubmed: 28004634
pmcid: 5178381
Somé AF, Zongo I, Compaoré YD, Sakandé S, Nosten F, Ouédraogo J-B et al (2014) Rosenthale Selection of Drug Resistance-Mediating P. falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrob Agents Chemother 58(7):3660–3665
doi: 10.1128/AAC.02406-14
pubmed: 24733476
pmcid: 4068591
Tinto H, Zoungrana EB, Coulibaly SO, Ouedraogo JB, Traoré M, Guiguemde TR et al (2000) Chloroquine and sulphadoxine-pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo-Dioulasso, Burkina Faso during a 3-year period 1998–2000. Tropical Med Int Health 7(11):925–930. https://doi.org/10.1046/j.1365-3156.2002.00952.x
doi: 10.1046/j.1365-3156.2002.00952.x
Tinto H, Sanou B, Dujardin JC, Ouedraogo JC, Overmeir CV, Erhart A et al (2005) Short report: Usefulness of the P. falciparum chloroquine resistance transporter T76 genotype failure index for the estimation of in vivo chloroquine resistance in Burkina Faso. Am J Trop Med Hyg 73(1):171–173
doi: 10.4269/ajtmh.2005.73.171
pubmed: 16014853
Basco LK, Ngane VF, Ndounga M, Same-Ekobo A, Youmba JC, Abodo RTO (2006) Molecular epidemiology of malaria in Cameroon. XIII. Analysis of Pfcrt mutations and in vitro chloroquine resistance. Am J Trop Med Hyg 75(3):388–395
doi: 10.4269/ajtmh.2006.75.388
pubmed: 16968911
Mahamat HA (2008) Etude de la relation entre la présence de la mutation Pfcrt 76T et l’efficacité thérapeutique de l’association artesunate amodiquine dans le traitement du paludisme simple à Plasmodium falciparum au Burkina Faso. Mémoire DEA de l’université polytechnique de Bobo-Dioulasso, p 47.
Nikiéma S, Sermé SS, Sombié S, Diarra A, Henry NB, Badoum ES (2019) Prevalence of Plasmodium Falciparum Chloroquine Resistance Transporter (Pfcrt 76T) mutation associated with antimalarial drug resistance in two different epidemiological setting (Banfora and Saponé) in Burkina Faso few years after the implementation of Artemisnine Based Combination Therapy (ACTs). Int J Pathogen Res 3(3–4):1–11
Menard S, Morlais I, Tahar R, Sayang C, Mayengue PI, Iriart X et al (2012) A Molecular monitoring of Plasmodium falciparum drug susceptibility at the time of the introduction of artemisinin-based combination therapy in Yaoundé, Cameroon: implications for the future. Malar J 11:113
doi: 10.1186/1475-2875-11-113
pubmed: 22498364
pmcid: 3368752
Zhao D, Zhang H, Ji P, Li S, Yang C, Liu Y et al (2021) Surveillance of Antimalarial Drug-Resistance Genes in Imported Plasmodium falciparum Isolates from Nigeria in Henan, China, 2012–2019. Front Cell Infect Microbiol 11:644576
doi: 10.3389/fcimb.2021.644576
pubmed: 33968801
pmcid: 8102827
Rana R, Khan N, Sandeepta S, Pati S, Das A, Bal M et al (2022) Molecular surveillance of anti-malarial drug resistance genes in P. falciparum isolates in Odisha India. Malar J 21:394. https://doi.org/10.1186/s12936-022-04403-3
doi: 10.1186/s12936-022-04403-3
pubmed: 36566182
pmcid: 9790123
Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN et al (2003) Reemergence of chloroquinesensitive P. falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187:1870–1875
doi: 10.1086/375419
pubmed: 12792863
Sondo P, Bihoun B, Kabore B, Tahita MC, Derra K, Rouamba T et al (2021) Polymorphisme de P. falciparum et mutations des gènes de résistance Pfcrt et Pfmdr1 dans la zone de Nanoro Burkina Faso. Pan African Med J 39:118. https://doi.org/10.11604/pamj.2021.39.118.26959
doi: 10.11604/pamj.2021.39.118.26959
Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y et al (2001) A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344(4):257–263. https://doi.org/10.1056/NEJM200101253440403
doi: 10.1056/NEJM200101253440403
pubmed: 11172152
Tinto H, Diallo S, Zongo I, Guiraud I, Valea I, Kazienga A et al (2014) Effectiveness of artesunate-amodiaquine vs artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial. Tropical Med Int Health 19(4):469–475. https://doi.org/10.1111/tmi.12274
doi: 10.1111/tmi.12274
Mahamar A, Summer KM, Levitt B, Freedman B, Traore A, Barry A et al (2022) Effect of three years seasonal malaria chemoprevention on molecular markers of resistance of P. falciparum to sulfadoxine–pyrimethamine and amodiaquine in Ouelessebougou Mali. Malar J 21:39. https://doi.org/10.1186/s12936-022-04059-z
doi: 10.1186/s12936-022-04059-z
pubmed: 35135546
pmcid: 8822718
Niba PTN, Nji AM, Chedjou JPK, Hansson H, Hocke EF, Ali IM et al (2023) Evolution of P. falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon. Int J Infect Dis 132:108–117
doi: 10.1016/j.ijid.2023.03.050
pubmed: 37028468
pmcid: 10182900
Voumbo-Matoumona DF, Kouna LC, Madamet M, Maghendji-Nzondo S, Pradines B, Lekana-Douki JB (2018) Prevalence of P. falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014. Infect Drug Resist 11:1329–1338
doi: 10.2147/IDR.S160164
pubmed: 30214253
pmcid: 6118251
Baba E, Hamade P, Kivumbi H, Marasciulo M, Maxwell K, Moroso D et al (2020) Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet 396(10265):1829–1840. https://doi.org/10.1016/S0140-6736(20)32227-3
doi: 10.1016/S0140-6736(20)32227-3
Gutman J, Kalilani L, Taylor S, Zhou Z, Wiegand RE, Thwai KL et al (2015) The A581G mutation in the gene encoding plasmodium falciparum dihydropteroate synthetase reduces the effectiveness of sulfadoxine–pyrimethamine preventive therapy in Malawian pregnant women. J Infect Dis 211(12):1997–2005. https://doi.org/10.1093/infdis/jiu836
doi: 10.1093/infdis/jiu836
pubmed: 25564249
pmcid: 4539907